<DOC>
	<DOCNO>NCT00486954</DOCNO>
	<brief_summary>EGF104578 two-part study ( Pilot part/Randomized part ) .Pilot part design find optimal ( best ) dose lapatinib paclitaxel give together , Randomized part design evaluate overall survival patient receive lapatinib paclitaxel compare patient receive paclitaxel .</brief_summary>
	<brief_title>Lapatinib Combination With Weekly Paclitaxel Patients With ErbB2 Amplified Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : Specific Information regarding warning , precaution , contraindication , adverse event , pertinent information investigational product may impact subject eligibility provide Investigator 's Brochure ( IB ) Pilot Part Subjects eligible enrollment Pilot Part study must meet following criterion : Signed informed consent Male female ; ≥ 20 year ( time give consent ) Any histologically cytologically confirm gastric carcinoma independent tumor ErbB2 status Subjects receive one prior regimen gastric carcinoma develop disease progression recurrence . The regimen must contain 5fluoropyrimidine and/or cisplatin Left ventricular ejection fraction ( LVEF ) within institutional range normal measure echocardiogram ( ECHO ) . Multigated acquisition ( MUGA ) scan accepted case echocardiogram perform inconclusive ( LVEF ≥50 % require normal range LVEF provide institution ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Able swallow retain oral medication Women men potential child must willing practice acceptable method birth control study Washout period prior last therapy follow ; Chemotherapy ( except agent ) 4 week ( I.V ) Chemotherapy ( except agent ) 2 week ( P.O ) Trastuzumab , Bevacizumab 4 week MitomycinC , nitrosourea 6 week Radiotherapy , Immunotherapy , Biologic therapy Surgery ( except minor surgical procedure ) 2 week Willing complete screening assessment outline protocol Adequate organ function define Table 2 Baseline Laboratory Values Able hospitalize PK analysis cycle 1 Life expectancy least 12 week first dose study treatment ) Randomized Part Subjects eligible enrollment Randomized Part study must meet following criterion : Signed informed consent Male female ; ≥ 20 year ( time give consent ) Histologically cytologically confirm gastric carcinoma document amplification ErbB2 fluorescence situ hybridization ( FISH ) primary metastatic tumor tissue Subjects receive one prior regimen gastric carcinoma define progression disease . The regimen must contain 5fluoropyrimidine and/or cisplatin Measurable lesion ( ) accord RECIST ( Response Evaluation Criteria Solid Tumors ) Left ventricular ejection fraction ( LVEF ) within institutional range normal measure echocardiogram . MUGA scan accept case echocardiogram perform inconclusive ( LVEF ≥50 % require normal range LVEF provide institution ) ECOG Performance Status 0 1 Able swallow retain oral medication Archived ( Biopsy ) tumor tissue available FISH test [ Wolff , 2007 ] central laboratory Women men potential child must willing practice acceptable method birth control study Washout period prior last therapy follow ; Chemotherapy ( except agent ) 4 week ( IV ) Chemotherapy ( except agent ) 2 week ( P.O ) Trastuzumab , Bevacizumab 4 week MitomycinC , nitrosourea 6 week Radiotherapy , Immunotherapy , Biologic therapy Surgery ( except minor surgical procedure ) 2 week Willing complete screening assessment outline protocol Adequate organ function define Table 2 Gastrectomy status depend result Pilot Part Life expectancy least 12 week first dose study treatment Table 2 Baseline Laboratory Values SYSTEM LABORATORY ( VALUES ) Hematologic : ANC ( absolute neutrophil count ) Hemoglobin : Platelets ( ≥ 2.0 × 10^9/L ) ( ≥ 9 g/dL ) ( ≥ 100 × 10^9/L ) Hepatic Albumin Serum bilirubin AST ALT ( ≥ 2.5 g/dL ) ( ≤ 1.25 x ULN ) ( ≤ 2.5 × ULN without liver metastasis ) ( ≤ 5 × ULN document liver metastasis ) Renal Serum Creatinine Calculate Creatinine Clearance ( see Section 11.3 ) ( ≤ 2.0 mg/dL ) OR ( ≥30 mL/min ) Exclusion criterion : Subjects meet follow criterion must enrol study : Pregnant lactate female anytime study Planned concurrent anticancer therapy ( chemotherapy , radiotherapy , immunotherapy , biologic therapy , hormonal therapy ) take investigational treatment Unresolved unstable , serious toxicity prior cancer treatment ( toxicity great grade 2 ) Peripheral neuropathy Grade 2 great Malabsorption syndrome , disease significantly affect gastrointestinal function . Subjects ulcerative colitis Crohn 's disease also exclude History malignancy . However , subject diseasefree 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma , eligible Concurrent disease condition would make subject inappropriate study participation serious medical disorder would interfere subject 's safety Life threaten infection Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent Known history uncontrolled symptomatic angina , arrhythmia , congestive heart failure Known history clinical evidence central nervous system ( CNS ) metastasis Concurrent treatment prohibit medication , include herbal remedy Chinese traditional medicine Concurrent treatment investigational agent within 28 day prior administration paclitaxel and/or lapatinib Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate paclitaxel , include polyethoxylated castor oil , alcohol , lapatinib excipients Anamnesis diagnosis pulmonary disorder , interstitial pneumonia , pulmonary fibrosis serious hypoxia Gastrectomy surgery Pilot Part study determine partial gastrectomy ( pylorus spar ) total/partial gastrectomy ( pylorus remove ) significant negative impact upon lapatinib PK safety profile Known history use EGFR agent ( except Trastuzumab ) Prior gastric cancer treatment include taxane .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>lapatinib</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>ErbB2</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Advanced gastric cancer</keyword>
</DOC>